Every one of those 1 sits in a single category, fda-approval. Stéphane Bancel is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Moderna, Inc. appears in 1 tracked Biotech story from August 6, 2026. The tracked stories average 2 original sources each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Moderna, Inc.
Every one of those 1 sits in a single category, fda-approval. Stéphane Bancel is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Moderna, Inc. appears in 1 tracked Biotech story from August 6, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Moderna, Inc.. Shared-story counts are live from our verified record — not editorial picks.
The U.S. FDA approved Moderna's mFLUSIVA, an mRNA seasonal influenza vaccine, for adults 50 and older. Data from two randomized trials, including a 40,805-subject Phase 3, supported the approval, with the 65+ cohort receiving accelerated approval. This milestone validates the mRNA platform beyond COVID-19 and positions Moderna to compete in the $5 billion+ global flu vaccine market.
